Esteroides y COVID-19: una revisión de la evidencia en crecimiento durante la pandemia

Gestne Aure; Fernando Carrera-Viñoles; Zully Andreina Requiz; María Morante; Julio Rodríguez

Autores/as

Gestne Aure
Fernando Carrera-Viñoles
Zully Andreina Requiz
María Morante
Julio Rodríguez

Palabras clave:

Esteroides, COVID-19, Dexametasona, SARS-CoV2

Resumen

El mecanismo específico por el cual los esteroides actuarían sobre la inflamación pulmonar sostenida, así como la definición del mejor fármaco a utilizar e incluso la duración adecuada del tratamiento, siguen siendo objetivo de estudio de los ensayos clínicos en curso. Como médicos clínicos, creemos que las potentes propiedades antiinflamatorias de los esteroides sintéticos están bien definidas, y aún falta evidencia definitiva de que otras estrategias antiinflamatorias proporcionen una mejor eficacia, al menos en el COVID-19. Aunque los esteroides sintéticos comparten una marcada acción antiinflamatoria y escasos efectos mineralocorticoides, su bioequivalencia y diferentes cinéticas deben considerarse cuidadosamente, debido a la elevada variabilidad de la farmacocinética individual, uso y prescripción adecuada de estos fármacos, ya que pueden desencadenar efectos adversos diversos que podrían impactar negativamente el curso clínico del paciente con COVID-19. Además, muchos de los fármacos actualmente considerados en el manejo del paciente con esta patología pueden potenciar la vida media y la aparición de efectos adversos de los corticoesteroides, o algunos efectos adversos de estos otros fármacos pueden simular complicaciones asociadas al uso de corticoesteroides, lo que podría conllevar a una suspensión precoz e inoportuna de los mismos. Números estudios clínicos y artículos basados en revisiones narrativas han servido de guías para los médicos clínicos en medio de esta pandemia, sin embargo, sus resultados deben interpretarse con cautela. Por estas razones, hemos realizado un análisis con base en el sistema GRADE de estos estudios para contrastar la información incluida en los estudios clínicos y minimizar el error de análisis.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Tang NL-S, Chan PK-S, Wong C-K, et al. Enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem. 2005; 55: 2333–2340.

Pang BS, Wang Z, Zhang LM, Tong ZH, Xu LL, Huang XX, Guo WJ, Zhu M, Wang C, Li XW, He ZP. Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chinese medical journal. 2003; 116(9).

Arabi YM, Balkhy HH, Hayden FG, et al. Middle East respiratory syndrome. N Engl J Med. 2017; 376: 584–94.

Waterer, Grant W., and Jordi Rello. "Steroids and COVID-19: we need a precision approach, not one size fits all." Infect Dis Ther. 2020; 16: 1-5.

Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-CoV pneumonia. Lancet. 2020; 29;395(10225):683.

Lewis SR, Pritchard MW, Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database of Systematic Reviews. 2019; 7.

RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19—preliminary report. The RECOVERY Trial.. N Engl J Med.. 2020.

SFrancesco Salton, Paola Confalonieri, G Umberto Meduri, Pierachille Santus, Sergio Harari, Raffaele Scala et al. "Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia." Open forum infectious diseases. 2020; 7(10).

Villar, Jesús, et al. "Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial." The Lancet Respiratory Medicine. 2020; 8(3): 267-276.

Tomazini, Bruno M., et al. "Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial." Jama. 2020; 324(13): 1307-1316.

Jeronimo CM, Farias ME, Val FF, Sampaio VS, Alexandre MA, Melo GC, Safe IP, Borba MG, Netto RL, Maciel AB, Neto JR. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clinical Infectious Diseases. 2020.

Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza.. Cochrane Database Syst Rev. 2016; 3.

Yu, He, et al.. "Can corticosteroids improve the outcomes of patients with Covid-19? A retrospective cohort study of patients within and outside the epicentre." Research Square. 2020.

Li Q, Li W, Jin Y, Xu W, Huang C, Li L, Huang Y, Fu Q, Chen L. Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study. Infectious diseases and therapy. 2020; 9: 823–836.

Nicolaides NC, Pavlaki AN, Alexandra MA, Chrousos GP. Glucocorticoid therapy and adrenal suppression. InEndotext [Internet] 2018 Oct 19. MDText. com, Inc. [Online].

Scaroni C, Armigliato M, Cannavò S. COVID-19 outbreak and steroids administration: are patients treated for Sars-Cov-2 at risk of adrenal insufficiency?. J Endocrinol Invest. 2020; 43(7): 1035-1036.

Ramiro S, Mostard RL, Magro-Checa C, Van Dongen CM, Dormans T, Buijs J, Gronenschild M, De Kruif MD, Van Haren EH, Van Kraaij T, Leers MP. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. 2020; 79(9).

Fadel R, Morrison AR, Vahia A, et al.. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020.

Ferraù F, Ceccato F, Cannavò S, Scaroni C. What we have to know about corticosteroids use during Sars-Cov-2 infection. Journal of endocrinological investigation. 2020; 28: 1-9.

Mebrahtu TF, Morgan AW, Kelley A, Baxter PD, Stewart PM, Pujades-Rodriguez M. Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England. J Clin Endocrinol Metab. 2019; 104(9): 3757-3767.

Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine. 2020; 180(7): 934–943.

Fernandez-Cruz A, Ruiz-Antoran B, Munoz-Gomez A, et al.. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality.. Fernandez-Cruz A, Ruiz-Antoran B, Munoz-Gomez A, et al. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother. 2020; 64(9).

Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020; 81(1).

Corral L, Bahamonde A, Arnaiz de las Revillas F, et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv. 2020.

Lu X, Chen T, Wang Y, Wang J, Yan F. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. Critical Care. 2020; 24(1): 1-4.

Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, Pivonello R, Pozza C, Sbardella E, Simeoli C, Scaroni C, Lenzi A. Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. J Endocrinol Invest. 2020 ; 43(5): 683-696.

Keller MJ, Kitsis EA, Arora S, Chen JT, Agarwal S, Ross MJ, Tomer Y, Southern W. Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19. Journal of hospital medicine. 2020; 1(15): 489-93.

Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, Dong N, Tong Q.. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan,. medRxiv. 2020.

Nelson BC, Laracy J, Shoucri S, Dietz D, Zucker J, Patel N, Sobieszczyk ME, Kubin CJ, Gomez-Simmonds A.. Clinical outcomes associated with methylprednisolone in mechanically ventilated patients with COVID-19. Clinical Infectious Diseases. 2020.